Axel Bolte - 24 Jun 2021 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Role
Chief Executive Officer, Director
Signature
/s/ Axel Bolte
Issuer symbol
INZY
Transactions as of
24 Jun 2021
Net transactions value
+$65,446
Form type
4
Filing time
25 Jun 2021, 07:58:07 UTC
Previous filing
20 May 2021
Next filing
28 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INZY Common Stock Options Exercise $65,452 +66,788 +35% $0.9800* 257,613 24 Jun 2021 Direct
transaction INZY Common Stock Sale $6.68 -66,788 -26% $0.000100* 190,825 24 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INZY Stock Option (right to buy) Options Exercise $0 -66,788 -40% $0.000000 100,480 24 Jun 2021 Common Stock 66,788 $0.9800 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a transfer by Reporting Person to HBM Partners AG in satisfaction of Reporting Person's obligation pursuant to a prior agreement with Reporting Person's former employer.
F2 These options are fully vested.